Back to School: How biopharma can reboot drug development. Access exclusive analysis here

12 + 23 = psoriatic relief

Johnson & Johnson thinks ustekinumab, a first-in-class monoclonal antibody against IL-12 and IL-23, could represent a paradigm shift in the treatment of psoriasis. Based on data presented last week, the MAb appears to have efficacy as good as the best marketed biologics plus improved convenience and a better safety profile.

At the World Congress of Dermatology in Buenos Aires, the company reported ustekinumab met the primary endpoint of PASI 75 score in

Read the full 723 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers